Last updated: 24 June 2024 at 9:42pm EST

Damian deGoa Net Worth



Mr. Damian deGoa biography

Damian deGoa is the CEO & Director at Liquidia Corp.

What is the salary of Mr deGoa?

As the CEO & Director of Liquidia Corp, the total compensation of Mr deGoa at Liquidia Corp is $417,308. There are 4 executives at Liquidia Corp getting paid more, with Neal Fowler having the highest compensation of $1,729,090.



How old is Mr deGoa?

Mr deGoa is 42, he's been the CEO & Director of Liquidia Corp since . There are 20 older and no younger executives at Liquidia Corp. The oldest executive at Liquidia Corp is Ralph Snyderman, 80, who is the Independent Director.

What's Mr deGoa's mailing address?

Damian's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, , MORRISVILLE, NC, 27560.

Insiders trading at Liquidia Corp

Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell és Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.



What does Liquidia Corp do?

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.



Liquidia Corp executives and stock owners

Liquidia Corp executives and other stock owners filed with the SEC include: